Brief: Transgene, NEC Corporation Present New Data On Individualised Cancer Vaccine TG4050

Transgene SA

06/06/2023 07:04

June 6 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE AND NEC PRESENT NEW DATA ON TG4050, AN
INDIVIDUALIZED
CANCER VACCINE, SHOWING IT INDUCES SPECIFIC IMMUNE RESPONSES
AGAINST HEAD AND NECK CARCINOMA AT ASCO 2023
    * ALL TRIAL PATIENTS TREATED WITH TG4050 MONOTHERAPY
CONTINUE TO
REMAIN IN REMISSION TO DATE
    * TRANSGENE AND NEC ARE PREPARING A PHASE II TRIAL TO
FURTHER
DEMONSTRATE POTENTIAL OF TG4050 AS AN ADJUVANT TREATMENT OF HEAD
AND NECK CANCER
    * NEW IMMUNOLOGICAL DATA ASSESSED BY TETRAMER STAINING
CONFIRMS
INDUCTION OF T CELL RESPONSES IN TREATED PATIENTS

Source text for Eikon:  ID:nBw1zKQ8ma 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))